Company intelligence / Profile preview

CinPhloro Pharma

Cincinnati, Ohio, United Statescinphloro.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CinPhloro Pharma is currently conducting the Phase 2 "enviva" study (NCT06153420) of CIN-103 for IBS-D. The first participant was dosed in February 2024. The study aims to enroll 450 adults with IBS-D to evaluate the safety, efficacy, and tolerability of CIN-103 over 12 weeks of treatment[1][8].

Therapeutic areas: Gastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CIN-103

Discontinued

Beyond the preview

Go deeper on CinPhloro Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CinPhloro Pharma.

Explore the full profile